Beta Bionics, Inc. BBNX
Medical/Dental Instruments · IPO 2025 · data as of November 13, 2026
Beta Bionics, Inc. (BBNX) is a healthcare company listed in the US with a market value of about $893M. In the twelve months to September 30, 2026 it had revenue of $127M and net income of -$83M, a net margin of -65.3%.
Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -19%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 89% below the current price.
About Beta Bionics
Beta Bionics is listed in the US and classified in medical/dental instruments, IPO year 2025. It was profitable in 0 of the last 3 years in our data. It spends 35% of revenue on research and development.
Score: 1.0 / 5
Checks passed
- Revenue growth above 10% last year
- Profit margin improving
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 3 years
| Fiscal year | TTM | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Revenue | $127M | $100M | $65M | $12M |
| Net income | -$83M | -$73M | -$55M | -$44M |
| Free cash flow | -$66M | -$56M | -$52M | -$33M |
| EPS (diluted) | $-1.83 | $-1.81 | $-8.60 | $-8.31 |
| Net margin | -65.3% | -73.0% | -84.1% | -367.6% |
| ROIC | — | -19.2% | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 14 analysts is $25.10, 53% above the current price; targets range from $16.00 to $30.40; the consensus rating is “Buy”; expected EPS is $-1.83 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is Beta Bionics stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 89% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Beta Bionics pay a dividend?
Not currently.
Is Beta Bionics a good stock to buy?
We do not give buy or sell advice. Beta Bionics scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.